feedback

Course Director

D. Ross Camidge, MD, PhD
D. Ross Camidge, MD, PhD

University of Colorado Cancer Center
Aurora, Colorado

Faculty

Alexander Drilon
Alexander Drilon, MD

Memorial Sloan Kettering Cancer Center
New York, New York

Pasi A. Jänne
Pasi A. Jänne, MD, PhD

Lowe Center for Thoracic Oncology
Belfer Institute for Applied Cancer Science
Harvard Medical School
Boston, Massachusetts

Mark A. Socinski
Mark A. Socinski, MD

Florida Hospital Cancer Institute
Orlando, Florida

David R. Spigel
David R. Spigel, MD

Sarah Cannon Research Institute
Nashville, Tennessee

Accredited by

Medical Learning Institute, Inc.

Activity Details

Credit Types:CME / CPE / CE
Credit Amount:2.0 Credits
Release Date:2017-Jul-28
Expiration Date:2018-Jul-27
Estimated Time for Completion:120 minutes
Registration Required:No
Cost:Free

Activity Description and Educational Objectives

Contemporary immunotherapies, targeted agents, and cytotoxic chemotherapies have expanded the NSCLC treatment landscape considerably, resulting in an abundance of options for clinicians and patients to consider. How can we navigate the clinical decisions in NSCLC in an evidence-based, patient-centric manner? How can the latest predictive tools help identify the best treatment for each patient at the right time? Where are we going next on the path towards increasing precision medicine in lung cancer?

In this activity based on a recent live symposium held at the 2017 American Society of Clinical Oncology Annual Meeting (ASCO 2017), a panel of experts discusses most up-to-date clinical data on current and emerging therapies, key ongoing trials, role of biomarkers in guiding clinical decisions, as well as clinical challenges and practicalities of everyday patient care. Supplemental infographic Practice Aids are provided to support learning and clinical application of evidence-based best practices.

Upon completion of this activity, participants will be able to:
  • Assess the efficacy/safety profiles and nuances of use of approved and investigational therapies for advanced NSCLC, including cytotoxic, targeted, and immunotherapeutic agents
  • Evaluate the role and use of various predictive factors that should guide treatment selection in advanced NSCLC
  • Develop individualized, evidence-based, patient-centric treatment plans throughout the continuum of advanced NSCLC

Target Audience

This activity has been designed to meet the educational needs of oncologists and other clinicians involved in the management of patients with lung cancer.

Nursing Education Purpose Statement

The purpose of this activity is to improve knowledge and competence of nurses concerning the treatment of lung cancer.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain CME/CE/CPE credit. There are no pre-requisites and there is no fee to participate in this activity or to receive CME/CE/CPE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: July 28, 2017 - July 27, 2018
Time to Complete: 120 minutes

Faculty & Disclosure / Conflict of Interest Policy

Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The associates of Medical Learning Institute, Inc., the accredited provider for this activity, and PVI, PeerView Institute for Medical Education do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME/CE/CPE activity during the past 12 months.

Course Director and Moderator
D. Ross Camidge, MD, PhD
Professor of Medicine/Oncology
Joyce Zeff Chair in Lung Cancer Research
Director, Thoracic Oncology
University of Colorado Cancer Center
Aurora, Colorado

D. Ross Camidge, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant for ARIAD Pharmaceuticals, Inc.; Celgene Corporation; Clovis Oncology; Genoptix; Novartis Pharmaceuticals Corporation; and Orion.
Other Financial or Material Support from G1 Therapeutics for Data and Safety Monitoring Board.

D. Ross Camidge, MD, PhD, does intend to discuss either non–FDA-approved or investigational use for the following products/devices: various cytotoxic, targeted, and immune-based therapies alone or in combinations, as well as testing platforms, relevant to ​lung cancer.

Faculty
Alexander Drilon, MD
Clinical Director, Developmental Therapeutics
Assistant Attending Physician, Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Alexander Drilon, MD, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from Foundation Medicine, Inc.
Honoraria from AstraZeneca; Blueprint Medicines; Exelixis, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Ignyta; and Loxo Oncology.

Alexander Drilon, MD, does intend to discuss either non–FDA-approved or investigational use for the following products/devices: various cytotoxic, targeted, and immune-based therapies alone or in combinations, as well as testing platforms, relevant to ​lung cancer.

Pasi A. Jänne, MD, PhD
Director, Lowe Center for Thoracic Oncology
Scientific Director, Belfer Institute for Applied Cancer Science
Professor of Medicine, Harvard Medical School
Boston, Massachusetts

Pasi A. Jänne, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant for ARIAD Pharmaceuticals, Inc.; AstraZeneca; Boehringer Ingelheim; Chugai Pharmaceutical Co.; Ignyta; Lilly; Loxo Oncology; Pfizer Inc.; and Roche/Genentech, Inc.

Pasi A. Jänne, MD, PhD, does intend to discuss either non–FDA-approved or investigational use for the following products/devices: various cytotoxic, targeted, and immune-based therapies alone or in combinations, as well as testing platforms, relevant to ​lung cancer.

Mark A. Socinski, MD
Executive Medical Director
Member, Thoracic Oncology Program
Florida Hospital Cancer Institute
Orlando, Florida

Mark A. Socinski, MD, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from Bristol-Myers Squibb; Celgene Corporation; Genentech; and Lilly.
Speakers Bureau participant with Bristol-Myers Squibb; Celgene Corporation; Genentech; and Lilly.
Advisory Board for Bristol-Myers Squibb; Celgene Corporation; Genentech; and Lilly.

Mark A. Socinski, MD, does intend to discuss either non–FDA-approved or investigational use for the following products/devices: various cytotoxic, targeted, and immune-based therapies alone or in combinations, as well as testing platforms, relevant to ​lung cancer.

David R. Spigel, MD
Chief Scientific Officer and Director, Lung Cancer Research Program
Sarah Cannon Research Institute
Nashville, Tennessee

David R. Spigel, MD, has no financial interests/relationships or affiliations in relation to this activity.

David R. Spigel, MD, does intend to discuss either non–FDA-approved or investigational use for the following products/devices: various cytotoxic, targeted, and immune-based therapies alone or in combinations, as well as testing platforms, relevant to ​lung cancer.

CME Reviewer
Vijaya R. Bhatt, MD
University of Nebraska Medical Center
Omaha, Nebraska

Vijaya R. Bhatt, MD, has no financial interests/relationships or affiliations in relation to this activity.

Nurse Reviewer
Bobbie Perrin, RN, OCN
Harrington Cancer Center
Amarillo, Texas

Bobbie Perrin, RN, OCN, has no financial interests/relationships or affiliations in relation to this activity.

CPE Reviewer
Teresa Haile, RPh, MBA
Blue Cross Blue Shield of Kansas City
Kansas City, Missouri

Teresa Haile, RPh, MBA, has no financial interests/relationships or affiliations in relation to this activity.

Medical Director
Kadrin Wilfong, MD
PVI, PeerView Institute for Medical Education

Kadrin Wilfong, MD, has no financial interests/relationships or affiliations in relation to this activity.

Disclaimer

The information provided at this CME/CE/CPE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

Providership, Credit & Support

Physicians
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this enduring material for a maximum of 2.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
Medical Learning Institute, Inc.
Provider approved by the California Board of Registered Nursing, Provider Number 15106, for 2.0 contact hour(s).

Pharmacists
ACPE The Medical Learning Institute, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Completion of this application-based activity provides for 2.0 contact hours (0.2 CEUs) of continuing pharmacy education credit. The Universal Activity Number for this activity is 0468-9999-17-010-H01-P.

Providership

This CME/CE/CPE activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

Support

This activity is supported by independent educational grants from AbbVie, Boehringer Ingelheim Pharmaceuticals, Inc., Celgene Corporation, Foundation Medicine, Inc., Genentech, and Merck & Co., Inc.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView Press or any of its partners, providers, and/or supporters.

Copyright © 2000-2017, PeerView Press

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.